Global Hematology Partnering 2010 to 2020 provides the full collection of Hematology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
Trends in Hematology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hematology partnering agreement structure Hematology partnering contract documents Top Hematology deals by value Most active Hematology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Hematology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hematology deals.
The report presents financial deal terms values for Hematology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Hematology dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Hematology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Hematology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Hematology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Hematology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Hematology partnering deals by specific Hematology target announced since 2010. The chapter is organized by specific Hematology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Hematology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Hematology partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hematology technologies and products.
Report scope Global Hematology Partnering 2010 to 2020 is intended to provide the reader with an in-depth understanding and access to Hematology trends and structure of deals entered into by leading companies worldwide.
Global Hematology Partnering 2010 to 2020 includes: Trends in Hematology dealmaking in the biopharma industry since 2010 Analysis of Hematology deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Hematology deal contract documents Comprehensive access to over 500 Hematology deal records The leading Hematology deals by value since 2010 Most active Hematology dealmakers since 2010
The report includes deals for the following indications: Agranulocytosis, Anemia, Haemolytic, Iron deficiency, Blood substitute, Disseminated intravascular coagulation (DIC), Hemophilia, Immune thrombocytopenic purpura, Neutropenia, Polycythemia, Thalassemia, Thrombocytopenia, Vitamin K Deficiency, Von-Willebrand disease, plus other hematological indications.
In Global Hematology Partnering 2010 to 2020, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Hematology Partnering 2010-2020 report provides comprehensive access to available deals and contract documents for over 500 hematology deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are the sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Endometrial Cancer Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Endometrial Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Endometrial Cancer Clinical trials scenario.This report provides top line data relating to the clinical trials on Endometrial...
Women’s Health - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Women’s Health - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Women’s Health pipeline products with comparative analysis of the products at various stages...
The Plasma Fractionation market studied is anticipated to grow with a CAGR of nearly 8.76%, during the forecast period. Certain factors that are driving the market growth include growing use of immunoglobulins in various therapeutic areas, rising geriatric population coupled with rise in prevalence of rare diseases, and increasing number of...
Amyloidosis - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2020, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape. Abnormal accumulation of amyloid protein in the tissues...
Warts - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2020, provides an overview of the Warts (Infectious Disease) pipeline landscape. Warts are skin growth that is caused by virus called human papillomavirus (HPV)....
Hyperalgesia - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hyperalgesia - Pipeline Review, H2 2020, provides an overview of the Hyperalgesia (Central Nervous System) pipeline landscape. Hyperalgesia is an increase in pain response. Predisposing...
Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020 Summary According to the recently published report ’Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020’; Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 16 molecules. Vascular...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.